查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1969252

基因编辑市场：按 CRISPR 技术、应用和最终用户划分 - 2026-2032 年全球预测

Gene Editing Market by CRISPR, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因编辑市场价值将达到 108.9 亿美元，到 2026 年将成长到 129.2 亿美元，到 2032 年将达到 368.5 亿美元，复合年增长率为 19.02%。

主要市场统计数据
基准年 2025 108.9亿美元
预计年份：2026年 129.2亿美元
预测年份 2032 368.5亿美元
复合年增长率 (%) 19.02%

基因编辑领域清晰权威的指南，全面涵盖技术进步、不断变化的管治以及不同相关人员的实际优先事项。

基因编辑技术已从小众科学探索发展成为重塑生物医学研究、农业生物技术和工业生物科学的核心能力。基于可程式设计核酸酶和RNA引导系统，这项基础科学如今能够对多种基因组和细胞类型进行精确修饰，加速假设检验并推动新治疗方法的开发。作为对此趋势的介绍，本报告重点关注其底层技术、转换流程、法律规范以及不断发展的供应商、服务供应商和终端用户生态系统之间的互动。

对正在积极重新定义发展重点和转化风险概况的关键技术、营运和监管转折点进行深入综合分析。

基因编辑技术的技术和製度演进的最后阶段正在带来若干变革性转变，从根本上改变了研发和商业化各个阶段的策略考量。首先，编辑技术的改进（包括可减少基因组环境附带损伤的精准编辑技术的进步）已将重点从概念验证转移到优化安全性和有效性范围。开发人员现在将正交检验方法、高解析度脱靶评估和全面的功能表征作为转化决策的先决条件。

对关税调整对基因编辑开发整个生命週期中的供应链韧性、筹资策略和营运连续性的影响进行严格分析。

调整进口关税和贸易壁垒的政策变化会对整个研发生态系统产生复杂的影响。当美国实施关税调整时，最直接的影响体现在实验室运作所需的专用设备、试剂和耗材的采购和分销方面。依赖进口设备和原材料的实验室将面临采购成本增加和潜在的延误，导致前置作业时间延长、库存缓衝增加以及供应商选择流程更加复杂。

透过多维细分框架对开发资源进行策略性分配，明确技术选择、应用需求和最终使用者行为。

细分市场为理解基因编辑技术的技术路径和应用主导的优先事项提供了一个切实可行的观点。基于 CRISPR 的市场分析通常着重于 Cas12、Cas13 和 Cas9，它们各自展现出独特的生化特性、标靶特异性和应用适用性。儘管 Cas9 在许多情况下仍然是 DNA 编辑的通用核酸酶，但 Cas12 和 Cas13 扩展了单链标靶化和 RNA 编辑能力，从而能够实现减少永久性基因组修饰和支持瞬时调控策略的方法。

区域比较评估突显了不同地区在法规、基础设施优势以及全球枢纽商业性和实际扩张的策略路径方面的细微差异。

区域趋势透过监管立场、人才库、资金筹措生态系统和产业基础设施的差异，影响基因编辑领域的创新轨迹和营运选择。在美洲，监管路径与强劲的私人投资和密集的临床开发生态系统紧密相连，二者共同加速转化项目，并为基础技术和服务创造稳健的市场。机构审查框架和集中式监管机构为临床应用提供了可预测的路径，而丰富的创业投资环境则支持平台公司和高风险、高回报计划的快速扩张。

对企业行为和伙伴关係模式进行策略探索，揭示平台开发者、服务供应商和临床赞助商如何合作推动转换进度。

基因编辑生态系中的企业行为因其策略方向、资本结构和营运能力而异。工具和试剂供应商专注于平台可靠性、批间一致性以及法规合规性文件，以满足探索性研究实验室和受监管生产的需求。这些供应商投资于品质系统和技术支援，以降低准入门槛，并帮助客户满足日益严格的检验要求。服务供应商和契约製造则优先考虑产能、製程稳健性和合规准备，以支援客户从临床前生产过渡到受监管的临床生产。

一系列可操作、有影响力的建议，营运经理和专案团队可以立即实施：加强转化研究的准备工作并降低风险。

研究机构和产业界的领导者必须采取实际行动，将科学潜力转化为永续的成果。首先，投资于整合分子表征、正交功能分析和标准化脱靶分析的检验框架。这有助于降低后续风险，并加强监管合规的基础。其次，儘早实现关键试剂和设备的供应商多元化，并验证替代来源的合格，以减轻采购衝击，维持研究的连续性。第三，将发行策略与分子设计同步进行。递送技术和基因编辑化学的协同开发通常比顺序开发更能带来可预测的转换进展。

透过整合文献摘要、专家访谈和跨細項分析，我们透过透明、以证据为导向的调查方法，创造出可操作的见解。

支持这些发现的研究途径结合了系统性的二手文献研究、有针对性的专家对话和迭代整合，以确保可靠的证据基础。二手文献分析利用了同行评审的文献、监管指导文件、专利申请和技术白皮书，以绘製技术发展轨迹并识别检验方法和发行策略中的反覆出现的主题。这项基础性综述建立了一个通用的知识库，并突显了需要更深入的质性研究的领域。

这是一份简洁、综合的分析报告，它透过连接技术进步、营运准备和监管合作，提出了负责任地推进基因编辑计画的连贯蓝图。

基因编辑技术正处于策略转折点，技术能力、监管进步和营运规范在此交汇，决定哪些项目能够从实验室概念验证走向实际应用。该领域的成熟不仅需要持续的技术创新，还需要严谨的营运实践、与监管机构的积极合作以及弥合能力差距的策略伙伴关係。那些能够协调分子设计和发行策略、实现供应链多元化并优先考虑严格检验的机构，可以降低转化风险，提高专案成功的可能性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 基因编辑市场：CRISPR

  • Cas12
  • Cas13
  • Cas9

第九章 基因编辑市场：依技术划分

  • 反义寡核苷酸
  • CRISPR-Cas9
  • Meganucleases
  • RNA引导的核酸酶
  • TALENs（转录活化因子样效应核酸酶）
  • ZFN（锌指核酸酶）

第十章 基因编辑市场：依应用领域划分

  • 动物基因工程
  • 基础研究
  • 生质能源
  • 细胞株工程
  • 诊断
  • 药物研发
  • 基因编辑
  • 植物基因工程
  • 疫苗研发

第十一章 基因编辑市场：依最终使用者划分

  • 学术和政府附属研究机构
  • 生物技术和製药公司
  • 受託研究机构（CRO）

第十二章 基因编辑市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 基因编辑市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 基因编辑市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国基因编辑市场

第十六章：中国基因编辑市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • GenScript Biotech Corporation
  • Illumina, Inc.
  • Lonza Group AG
  • Merck KGaA
  • New England Biolabs, Inc.
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-535C6291877E

The Gene Editing Market was valued at USD 10.89 billion in 2025 and is projected to grow to USD 12.92 billion in 2026, with a CAGR of 19.02%, reaching USD 36.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.89 billion
Estimated Year [2026] USD 12.92 billion
Forecast Year [2032] USD 36.85 billion
CAGR (%) 19.02%

A clear and authoritative orientation to the gene editing landscape that frames technological progress, governance shifts, and practical priorities for varied stakeholders

Gene editing has transitioned from a niche scientific pursuit to a central capability that reshapes biomedical research, agricultural biotechnology, and industrial biosciences. The underlying science, anchored by programmable nucleases and RNA-guided systems, now enables precise modifications across a range of genomes and cell types, accelerating hypothesis testing and enabling novel therapeutic modalities. As an introduction to this landscape, the focus here is on the interplay between enabling technologies, translational pipelines, regulatory architecture, and the evolving ecosystem of suppliers, service providers, and end users.

Over recent years, the field has matured through iterative innovation in enzyme engineering, delivery platforms, and analytical methods. These technical improvements have expanded the scope of feasible projects, from single-gene edits in cell lines to complex multiplexed interventions in plants and animals. At the same time, the governance environment has become more active, with regulators and institutional review bodies clarifying expectations for clinical use, environmental release, and biosafety. This dual evolution of capability and oversight defines the strategic priorities for organizations investing in gene editing: demonstrating robust on-target performance, minimizing unintended outcomes, and ensuring compliant pathways to application.

In practical terms, stakeholders must balance scientific ambition with operational realities. Research institutions and commercial developers are increasingly focused on reproducible workflows, scalable manufacturing of biological materials, and robust quality-control frameworks. These operational improvements support both discovery and downstream development, enabling faster iteration cycles while maintaining data integrity. The remainder of this executive summary outlines the transformative shifts in the landscape, segmentation perspectives, regional dynamics, company-level behaviors, and pragmatic recommendations to inform strategic decision-making.

An incisive synthesis of the pivotal technological, operational, and regulatory shifts that are actively redefining development priorities and translational risk profiles

The last phase of technical and institutional evolution in gene editing has produced several transformative shifts that materially alter strategic considerations across research, development, and commercialization. First, refinement of editing modalities - including advances in precision editing that reduce collateral damage to genomic context - has shifted emphasis from proof of concept to optimization of safety and efficacy margins. Developers now prioritize orthogonal validation methods, high-resolution off-target assessment, and comprehensive functional characterization as prerequisites for translational decisions.

Second, delivery science has emerged as a central bottleneck and opportunity simultaneously. Improvements in viral vectors, lipid nanoparticles, and physical delivery techniques have increased the range of usable tissue types, but each approach imposes trade-offs between payload capacity, immunogenicity, and repeat dosing. Consequently, organizations are pursuing parallel strategies that combine editing chemistry innovation with bespoke delivery engineering to meet application-specific constraints.

Third, data-driven approaches are accelerating design cycles. Computational modeling, machine learning-enabled guide selection, and multiplexed screening platforms reduce empirical cycles and improve predictability. These approaches also enable more efficient candidate triage and risk assessment, supporting leaner development portfolios and clearer go/no-go criteria. Finally, regulatory and societal conversations around acceptable use, benefit-risk calculus, and equitable access are shaping commercial strategies; firms are embedding ethical and compliance considerations earlier in program design to avoid late-stage friction and to strengthen stakeholder trust.

A rigorous analysis of how tariff adjustments affect supply chain resilience, procurement strategies, and operational continuity across the gene editing development lifecycle

Policy changes that adjust import duties and trade barriers exert a complex set of influences across research and development ecosystems. When the United States implements tariff adjustments, the immediate impact is most visible in the procurement and distribution of specialized instrumentation, reagents, and consumables that underpin laboratory operations. Laboratories that rely on imported equipment or raw materials face elevated procurement costs and potential delays, which in turn incentivize longer lead times, increased inventory buffers, and expanded supplier qualification efforts.

Beyond procurement dynamics, tariffs contribute to shifts in global supply chain architecture. Organizations evaluate the resilience of existing vendor relationships and may accelerate efforts to qualify domestic or regional suppliers to reduce exposure to cross-border trade friction. This adaptation often entails additional validation work and qualification cycles that temporarily divert technical resources away from discovery activities. In parallel, multinational collaborations can encounter contractual renegotiations where duties alter total landed costs, creating friction for cross-border clinical manufacturing and collaborative research agreements.

Longer-term implications concern strategic sourcing and manufacturing footprint decisions. Service providers and contract manufacturers reassess the geographic distribution of their capabilities to mitigate tariff-related volatility, which can spur investment in regional capacity expansion or in vertical integration to internalize critical processes. Importantly, tariff-driven changes interact with regulatory requirements and clinical timelines; organizations that proactively manage supplier diversification and inventory risk are better positioned to maintain research continuity and to align operational plans with regulatory milestones.

A multidimensional segmentation framework that clarifies technology choices, application demands, and end user behaviors to guide strategic allocation of development resources

Segmentation offers a practical lens to understand technological pathways and application-driven priorities within gene editing. Based on CRISPR, market analysis commonly examines Cas12, Cas13, and Cas9, each of which presents distinct biochemical properties, target specificities, and application fit. Cas9 remains a versatile nuclease for DNA editing in many contexts, while Cas12 and Cas13 expand capabilities for single-strand targeting and RNA editing, enabling approaches that reduce permanent genomic alteration and that support transient modulation strategies.

Based on Technology, studies evaluate modalities including Antisense oligonucleotides, CRISPR-Cas9, Meganucleases, RNA-guided nucleases, TALENs (Transcription Activator-Like Effector Nucleases), and ZFNs (Zinc Finger Nucleases). Each technology exhibits a different balance of specificity, ease of design, and delivery constraints, which informs selection criteria for therapeutic programs versus agricultural or industrial applications. Antisense oligonucleotides and RNA-guided strategies commonly serve as lower-barrier interventions for transient gene modulation, whereas engineered nucleases like TALENs and ZFNs continue to play roles where locus-specific considerations demand alternative architectures.

Based on Application, the field spans Animal Genetic Engineering, Basic Research, Bioenergy, Cell Line Engineering, Diagnostics, Drug Development, Gene Editing, Plant Genetic Engineering, and Vaccine Development. Application context drives requirements for durability, target tissue, regulatory scrutiny, and acceptable risk, influencing both project timelines and technical choices. For example, diagnostics and cell line engineering prioritize rapid turnaround and reproducibility, while vaccine development and plant engineering emphasize scalability and environmental considerations.

Based on End User, the landscape comprises Academic & Government Research Institutes, Biotechnology & Pharmaceutical Companies, and Contract Research Organizations (CROs). Each end user segment exhibits unique procurement behaviors, risk tolerances, and collaboration models; academic institutions focus on exploratory research and publishable outputs, commercial developers aim for clinical translation and IP protection, and CROs provide operational capacity and regulatory-compliant processes that bridge discovery and commercial manufacturing. Understanding these segmentation axes in tandem enables more precise allocation of R&D resources and clearer prioritization of capability investments.

A comparative regional assessment that highlights regulatory nuances, infrastructure strengths, and strategic pathways for commercial and translational expansion across global hubs

Regional dynamics shape the innovation trajectory and operational choices in gene editing through differences in regulatory postures, talent pools, funding ecosystems, and industrial infrastructure. In the Americas, regulatory pathways are coupled with strong private investment and a dense clinical development ecosystem, which together accelerate translational programs and create robust markets for enabling technologies and services. Institutional review frameworks and centralized regulatory agencies provide predictable pathways for clinical translation, while a rich venture capital environment supports rapid scaling of platform companies and high-risk, high-reward projects.

In Europe, Middle East & Africa, stakeholders navigate a more heterogeneous regulatory environment where national approaches vary, and cross-border harmonization matters for multicountry trials and approvals. Europe's emphasis on ethical frameworks and public engagement shapes program design, particularly for environmental and agricultural applications. Public funding and collaborative consortia remain important drivers of precompetitive research, and capacity-building initiatives continue to expand access to advanced laboratory infrastructure across the region.

The Asia-Pacific region demonstrates rapid capacity expansion, large talent pipelines, and growing manufacturing capabilities. Regulatory approaches in several jurisdictions are evolving to support biotech innovation, and government-led initiatives frequently prioritize strategic sectors such as agriculture and healthcare. Combined with competitive manufacturing and supply chain ecosystems, this region is increasingly important for both clinical development and production of reagents and instruments. Each regional context requires tailored strategies for partnerships, regulatory engagement, and commercialization that reflect local regulatory expectations and market access considerations.

A strategic exploration of company behaviors and partnership models that reveal how platform developers, service providers, and clinical sponsors align to drive translational progress

Company behavior within the gene editing ecosystem varies by strategic orientation, capital structure, and operational capability. Tool and reagent providers focus on platform reliability, batch consistency, and regulatory-grade documentation to serve both discovery labs and regulated manufacturing. These suppliers invest in quality systems and technical support to reduce adoption friction and to enable customers to meet increasingly stringent validation requirements. Service providers and contract manufacturers emphasize capacity, process robustness, and compliance readiness to support clients moving from preclinical work to regulated clinical production.

Therapeutic developers prioritize target validation, clinical translation pathways, and risk mitigation strategies that align with regulatory expectations. Early-stage companies often concentrate on platform differentiation and IP position, while later-stage developers focus on clinical trial design, safety monitoring, and market access planning. Across the ecosystem, strategic partnerships and alliances serve as accelerators: collaborations between platform companies and clinical developers enable access to specialized chemistry or delivery solutions, while service-provider partnerships compress development timelines through integrated offerings.

Investment and M&A activity reflect the desire to consolidate capabilities and secure vertical integration in critical areas such as delivery and manufacturing. Companies that maintain clear go-to-market strategies, that invest in translational expertise, and that align product development with regulatory milestones are better positioned to capture opportunities and to de-risk program portfolios. Organizational agility, coupled with demonstrable quality systems, determines the pace at which firms can translate scientific advances into clinical and commercial outcomes.

A set of pragmatic, high-impact recommendations that operational leaders and program teams can implement immediately to strengthen translational readiness and risk mitigation

Leaders in research organizations and industry must act deliberately to translate scientific promise into durable outcomes. First, invest in integrated validation frameworks that combine molecular characterization, orthogonal functional assays, and standardized off-target analysis; this reduces downstream risk and strengthens regulatory narratives. Second, diversify supplier relationships early and qualify alternative sources for critical reagents and instruments to mitigate procurement shocks and to maintain research continuity. Third, embed delivery strategy alongside molecular design; co-development of delivery and editing chemistry often yields more predictable translational trajectories than sequential development.

Fourth, adopt data-driven design workflows that leverage computational prediction, high-throughput screening, and experimental feedback loops to accelerate candidate selection and to reduce iterative cycles. Fifth, engage regulators and ethics bodies proactively, sharing preclinical evidence and trial design rationale to reduce surprises and to align on safety requirements. Sixth, cultivate cross-sector partnerships with manufacturing and supply chain specialists to scale from proof of concept to regulated production while preserving quality systems and documentation.

Seventh, develop workforce capabilities by investing in training programs that bridge wet-lab expertise and translational project management; a multidisciplinary talent base accelerates program execution and improves governance. Finally, prioritize transparent stakeholder communication about benefit-risk considerations and risk-mitigation measures to build public trust and to support smoother pathways for clinical and agricultural applications. These actionable steps help organizations navigate technical complexity, regulatory expectations, and market uncertainties with greater confidence.

A transparent and evidence-driven methodology that integrates literature synthesis, expert interviews, and cross-segmentation analysis to produce actionable intelligence

The research approach underlying these insights combined systematic secondary research, targeted expert engagement, and iterative synthesis to ensure a robust evidence base. Secondary analysis drew on peer-reviewed literature, regulatory guidance documents, patent filings, and technical white papers to map technological trajectories and to identify recurring themes in validation practices and delivery strategies. This foundational review established a common knowledge baseline and highlighted areas requiring deeper qualitative inquiry.

Primary research involved structured interviews with subject-matter experts across academia, industry, and regulatory affairs. These conversations explored practical challenges in program execution, supply chain resilience, and compliance management, and they provided firsthand perspectives on the operational implications of recent technological advances. Triangulation of secondary and primary inputs ensured that findings reflect both documented evidence and real-world operational experience.

Analytic methods included qualitative coding to identify thematic patterns, cross-segmentation comparison to surface differences in technology and application fit, and scenario analysis to test supply chain and regulatory sensitivities. Quality assurance measures included expert review cycles and reconciliation of divergent viewpoints to minimize bias. The resulting synthesis emphasizes actionable intelligence that is directly relevant to program leaders, procurement teams, and strategic planners engaged in gene editing research and commercialization.

A concise synthesis that connects technical progress, operational readiness, and regulatory engagement into a coherent roadmap for advancing gene editing programs responsibly

Gene editing stands at a strategic inflection point where technological capability, regulatory evolution, and operational discipline converge to determine which programs progress from laboratory proof of concept to real-world application. The field's maturation requires not only continued technical innovation but also disciplined operational practices, proactive regulatory engagement, and strategic partnerships that bridge capability gaps. Organizations that align molecular design with delivery strategy, that diversify supply chains, and that prioritize rigorous validation will reduce translational risk and improve the probability of program success.

At the regional and organizational level, tailored approaches are essential. Regulatory nuances, infrastructure realities, and workforce strengths vary across geographies, and strategic plans must reflect these contextual differences. Companies and institutions should combine near-term operational resilience measures with longer-term investments in platform capabilities and translational talent. By doing so, they can both capitalize on immediate opportunities and build durable competitive advantages.

Ultimately, success in this domain depends on integrating scientific excellence with pragmatic execution. Clear governance, transparent stakeholder communication, and a disciplined approach to risk management will enable the most promising gene editing programs to move from concept to impact, delivering therapeutic, agricultural, and industrial benefits while maintaining public trust and regulatory compliance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Editing Market, by CRISPR

  • 8.1. Cas12
  • 8.2. Cas13
  • 8.3. Cas9

9. Gene Editing Market, by Technology

  • 9.1. Antisense oligonucleotides
  • 9.2. CRISPR-Cas9
  • 9.3. Meganucleases
  • 9.4. RNA-guided nucleases
  • 9.5. TALENs (Transcription Activator-Like Effector Nucleases)
  • 9.6. ZFNs (Zinc Finger Nucleases)

10. Gene Editing Market, by Application

  • 10.1. Animal Genetic Engineering
  • 10.2. Basic Research
  • 10.3. Bioenergy
  • 10.4. Cell Line Engineering
  • 10.5. Diagnostics
  • 10.6. Drug Development
  • 10.7. Gene Editing
  • 10.8. Plant Genetic Engineering
  • 10.9. Vaccine Development

11. Gene Editing Market, by End User

  • 11.1. Academic & Government Research Institutes
  • 11.2. Biotechnology & Pharmaceutical Companies
  • 11.3. Contract Research Organizations (CROs)

12. Gene Editing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Editing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Editing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Gene Editing Market

16. China Gene Editing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. Danaher Corporation
  • 17.8. GenScript Biotech Corporation
  • 17.9. Illumina, Inc.
  • 17.10. Lonza Group AG
  • 17.11. Merck KGaA
  • 17.12. New England Biolabs, Inc.
  • 17.13. PerkinElmer, Inc.
  • 17.14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE EDITING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE EDITING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE EDITING MARKET SIZE, BY CRISPR, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE EDITING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE EDITING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE EDITING MARKET SIZE, BY CAS12, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE EDITING MARKET SIZE, BY CAS12, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE EDITING MARKET SIZE, BY CAS12, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE EDITING MARKET SIZE, BY CAS13, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE EDITING MARKET SIZE, BY CAS13, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE EDITING MARKET SIZE, BY CAS13, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE EDITING MARKET SIZE, BY CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE EDITING MARKET SIZE, BY CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE EDITING MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE EDITING MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE EDITING MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE EDITING MARKET SIZE, BY CRISPR-CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE EDITING MARKET SIZE, BY CRISPR-CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE EDITING MARKET SIZE, BY CRISPR-CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE EDITING MARKET SIZE, BY MEGANUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE EDITING MARKET SIZE, BY MEGANUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE EDITING MARKET SIZE, BY MEGANUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE EDITING MARKET SIZE, BY RNA-GUIDED NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE EDITING MARKET SIZE, BY RNA-GUIDED NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE EDITING MARKET SIZE, BY RNA-GUIDED NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE EDITING MARKET SIZE, BY TALENS (TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE EDITING MARKET SIZE, BY TALENS (TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE EDITING MARKET SIZE, BY TALENS (TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE EDITING MARKET SIZE, BY ZFNS (ZINC FINGER NUCLEASES), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE EDITING MARKET SIZE, BY ZFNS (ZINC FINGER NUCLEASES), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE EDITING MARKET SIZE, BY ZFNS (ZINC FINGER NUCLEASES), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE EDITING MARKET SIZE, BY ANIMAL GENETIC ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE EDITING MARKET SIZE, BY ANIMAL GENETIC ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE EDITING MARKET SIZE, BY ANIMAL GENETIC ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE EDITING MARKET SIZE, BY BIOENERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE EDITING MARKET SIZE, BY BIOENERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE EDITING MARKET SIZE, BY BIOENERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE EDITING MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE EDITING MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE EDITING MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE EDITING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE EDITING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE EDITING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE EDITING MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE EDITING MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE EDITING MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE EDITING MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE EDITING MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE EDITING MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE EDITING MARKET SIZE, BY PLANT GENETIC ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE EDITING MARKET SIZE, BY PLANT GENETIC ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE EDITING MARKET SIZE, BY PLANT GENETIC ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE EDITING MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE EDITING MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE EDITING MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE EDITING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE EDITING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE EDITING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE EDITING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE EDITING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE EDITING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS GENE EDITING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA GENE EDITING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GCC GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 118. GCC GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. GCC GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. G7 GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. G7 GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 133. G7 GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. G7 GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. G7 GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NATO GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. NATO GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 138. NATO GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NATO GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)